- Home
- MGIH vs HOTH Comparison
MGIH vs HOTH Comparison
Compare MGIH & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIH
- HOTH
- Stock Information
- Founded
- MGIH 1978
- HOTH 2017
- Country
- MGIH Hong Kong
- HOTH United States
- Employees
- MGIH N/A
- HOTH N/A
- Industry
- MGIH Publishing
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- MGIH Consumer Discretionary
- HOTH Health Care
- Exchange
- MGIH Nasdaq
- HOTH Nasdaq
- Market Cap
- MGIH 18.0M
- HOTH 15.6M
- IPO Year
- MGIH 2023
- HOTH 2019
- Fundamental
- Price
- MGIH $1.65
- HOTH $1.28
- Analyst Decision
- MGIH
- HOTH Strong Buy
- Analyst Count
- MGIH 0
- HOTH 3
- Target Price
- MGIH N/A
- HOTH $4.00
- AVG Volume (30 Days)
- MGIH 14.3K
- HOTH 433.6K
- Earning Date
- MGIH 08-05-2025
- HOTH 05-12-2025
- Dividend Yield
- MGIH N/A
- HOTH N/A
- EPS Growth
- MGIH N/A
- HOTH N/A
- EPS
- MGIH N/A
- HOTH N/A
- Revenue
- MGIH $28,866,993.00
- HOTH N/A
- Revenue This Year
- MGIH N/A
- HOTH N/A
- Revenue Next Year
- MGIH N/A
- HOTH N/A
- P/E Ratio
- MGIH N/A
- HOTH N/A
- Revenue Growth
- MGIH N/A
- HOTH N/A
- 52 Week Low
- MGIH $1.32
- HOTH $0.58
- 52 Week High
- MGIH $6.83
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- MGIH 57.13
- HOTH 50.15
- Support Level
- MGIH $1.52
- HOTH $1.23
- Resistance Level
- MGIH $1.68
- HOTH $1.40
- Average True Range (ATR)
- MGIH 0.06
- HOTH 0.11
- MACD
- MGIH 0.01
- HOTH -0.02
- Stochastic Oscillator
- MGIH 81.25
- HOTH 27.50
About MGIH Millennium Group International Holdings Limited
Millennium Group International Holdings Ltd is a paper-based packaging solutions supplier. It offers paper-based inner and outer packaging products which can be broadly categorized into packaging products, Packaging products supply chain management solutions and corrugated products.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).